Yahoo · Oct 9, 2026
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $510.08, marking a +1.36% move from the previous day.
NYSE · VRTX
Vertex Pharmaceuticals Incorporated
Healthcare · Biotechnology
$510.08
Up+$6.83 (+1.36%)
Updated Oct 10, 2026, 8:00 PM
SID Score
6.3/10
Composite research score
Smart Money
52/100
Neutral
- Market cap
- 114.46B
- P/E ratio
- 31.02
- Dividend yield
- 0.00%
- 52-week range
- $412.27 – $560.25
- Volume
- 1.48M
- Avg. volume
- 1.51M
Price performance · VRTX
VRTX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
VRTX closed at $510.08 after 21 trading sessions, down 1.04% for the selected period.
- Last close
- $510.08
- Period change
- -1.04%
- Period low
- $502.31
- Period high
- $527.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $502.11 | $514.90 | $502.06 | $510.08 | 1.48M |
| Oct 8, 2026 | $503.14 | $507.87 | $498.90 | $503.25 | 1.49M |
| Oct 7, 2026 | $504.075 | $511.505 | $503.942 | $505.64 | 806.84K |
| Oct 6, 2026 | $505.00 | $507.41 | $496.325 | $502.31 | 775.07K |
| Oct 5, 2026 | $504.78 | $506.01 | $496.15 | $503.50 | 915.14K |
| Oct 2, 2026 | $509.50 | $509.50 | $499.95 | $504.73 | 939.66K |
| Oct 1, 2026 | $522.39 | $523.515 | $505.27 | $506.74 | 1.19M |
| Sep 30, 2026 | $525.26 | $529.72 | $522.74 | $522.81 | 1.15M |
| Sep 29, 2026 | $522.22 | $529.46 | $519.245 | $526.73 | 688.93K |
| Sep 28, 2026 | $524.27 | $529.89 | $521.16 | $527.67 | 824.74K |
| Sep 25, 2026 | $522.55 | $527.69 | $518.92 | $526.19 | 756.21K |
| Sep 24, 2026 | $515.56 | $528.99 | $515.30 | $522.38 | 941.06K |
| Sep 23, 2026 | $515.60 | $525.4296 | $509.56 | $516.34 | 1.21M |
| Sep 22, 2026 | $521.69 | $525.97 | $508.1426 | $514.99 | 1.39M |
| Sep 21, 2026 | $506.85 | $514.10 | $501.01 | $510.72 | 906.68K |
| Sep 18, 2026 | $516.34 | $518.10 | $505.01 | $508.34 | 2.43M |
| Sep 17, 2026 | $518.35 | $519.07 | $510.195 | $516.34 | 900.05K |
| Sep 16, 2026 | $513.80 | $517.95 | $511.35 | $513.26 | 638.51K |
| Sep 15, 2026 | $519.94 | $519.94 | $511.001 | $514.63 | 824.89K |
| Sep 14, 2026 | $522.17 | $525.29 | $514.655 | $519.51 | 837.11K |
| Sep 11, 2026 | $522.10 | $522.10 | $511.81 | $515.44 | 875.64K |
Latest VRTX news
The latest Smart Investors Daily articles mentioning VRTX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
VRTX research
Overview
Company profile and research snapshot.
Company profile
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $483.00
- Implied upside
- —
- Analysts
- 23
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Outperform | — |
| Sep 28, 2026 | UBS | Buy | — |
| Sep 11, 2026 | JP Morgan | Overweight | — |
| Sep 2, 2026 | Morgan Stanley | Overweight | — |
| Aug 5, 2026 | Truist Securities | Buy | — |
News briefing
Generated Oct 10, 2026, 7:01 PM
Why Is VRTX Up Today?
Vertex Pharmaceuticals gained 1.36% today as positive analyst sentiment and promising clinical data continue to support investor confidence in the company's pipeline. RBC Capital's recent price target raise to $576 and ongoing presentations of ALYFTREK® efficacy data are reinforcing the market's bullish outlook on the biotech firm.
Bottom line: Vertex is benefiting from a combination of positive analyst momentum, strong clinical data, and growing institutional interest, evidenced by today's modest 1.36% gain. While the company's cystic fibrosis franchise shows continued promise with expanding patient populations, investors should remain attentive to regulatory risks, competitive threats, and the upcoming earnings report as key factors that could influence near-term performance.
Yahoo · Oct 9, 2026
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
BOSTON, October 09, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversib
Yahoo · Oct 9, 2026
Is Vertex Stock Worth More Than Its Competitors?
Vertex Pharmaceuticals (VRTX) stock trades at 29.0 times earnings. That valuation prices the company higher than Regeneron and Incyte, two of its biotech peers. Vertex does generate the highest operating margin among its group of five companies, but its sales are growing more slowly than at three of the other four. So how much more are you paying for Vertex, and what do you get for it.
Benzinga · Oct 9, 2026
Vertex Presents Study Reporting ALYFTREK Data Shows Pancreatic Function Recovery In Some Children Ages 2–5 With Cystic Fibrosis
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented -Vertex
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
